NexImmune, Inc.
NEXI · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| R&D Expenses | $18 | $47 | $37 | $18 |
| G&A Expenses | $13,001 | $16 | $16 | $10 |
| SG&A Expenses | $10 | $16 | $16 | $10 |
| Sales & Mktg Exp. | -$12,991 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$1 | -$1 | -$1 |
| Operating Expenses | $28 | $62 | $52 | $27 |
| Operating Income | -$29 | -$63 | -$53 | -$28 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$3 | $1 | $2 | -$2 |
| Pre-Tax Income | -$32 | -$63 | -$51 | -$30 |
| Tax Expense | $0 | -$577 | $1 | $2 |
| Net Income | -$32 | $514 | -$52 | -$32 |
| % Margin | – | – | – | – |
| EPS | -30.82 | 534.29 | -56.67 | -34.76 |
| % Growth | -105.8% | 1,042.8% | -63% | – |
| EPS Diluted | -30.82 | 534.29 | -56.67 | -34.76 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $1 | $2 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$28 | -$61 | -$49 | -$28 |
| % Margin | – | – | – | – |